Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical T...
SYDNEY, July 22, 2019 /PRNewswire-AsiaNet/-- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia's inves...
Authors: LATEST ASIANET NEWS RELEASES